PMC:7376974 / 13930-15262
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T56","span":{"begin":72,"end":75},"obj":"Body_part"},{"id":"T57","span":{"begin":135,"end":138},"obj":"Body_part"},{"id":"T58","span":{"begin":309,"end":316},"obj":"Body_part"},{"id":"T59","span":{"begin":411,"end":414},"obj":"Body_part"},{"id":"T60","span":{"begin":574,"end":577},"obj":"Body_part"},{"id":"T61","span":{"begin":655,"end":658},"obj":"Body_part"},{"id":"T62","span":{"begin":861,"end":866},"obj":"Body_part"},{"id":"T63","span":{"begin":939,"end":943},"obj":"Body_part"},{"id":"T64","span":{"begin":1167,"end":1172},"obj":"Body_part"},{"id":"T65","span":{"begin":1250,"end":1257},"obj":"Body_part"},{"id":"T66","span":{"begin":1274,"end":1286},"obj":"Body_part"}],"attributes":[{"id":"A56","pred":"fma_id","subj":"T56","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A57","pred":"fma_id","subj":"T57","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A58","pred":"fma_id","subj":"T58","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A59","pred":"fma_id","subj":"T59","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A60","pred":"fma_id","subj":"T60","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A61","pred":"fma_id","subj":"T61","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A62","pred":"fma_id","subj":"T62","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A63","pred":"fma_id","subj":"T63","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A64","pred":"fma_id","subj":"T64","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A65","pred":"fma_id","subj":"T65","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A66","pred":"fma_id","subj":"T66","obj":"http://purl.org/sig/ont/fma/fma62925"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"141","span":{"begin":123,"end":128},"obj":"Gene"},{"id":"142","span":{"begin":185,"end":190},"obj":"Gene"},{"id":"143","span":{"begin":72,"end":77},"obj":"Species"},{"id":"144","span":{"begin":135,"end":140},"obj":"Species"},{"id":"145","span":{"begin":197,"end":202},"obj":"Species"},{"id":"146","span":{"begin":204,"end":209},"obj":"Species"},{"id":"147","span":{"begin":215,"end":221},"obj":"Species"},{"id":"148","span":{"begin":323,"end":340},"obj":"Species"},{"id":"149","span":{"begin":431,"end":435},"obj":"Species"},{"id":"150","span":{"begin":436,"end":453},"obj":"Species"},{"id":"151","span":{"begin":782,"end":796},"obj":"Species"},{"id":"152","span":{"begin":873,"end":889},"obj":"Species"},{"id":"153","span":{"begin":974,"end":988},"obj":"Species"},{"id":"154","span":{"begin":1067,"end":1077},"obj":"Species"},{"id":"155","span":{"begin":1179,"end":1183},"obj":"Species"},{"id":"156","span":{"begin":1237,"end":1241},"obj":"Species"},{"id":"157","span":{"begin":1267,"end":1271},"obj":"Species"},{"id":"158","span":{"begin":498,"end":509},"obj":"Species"},{"id":"159","span":{"begin":701,"end":705},"obj":"Species"},{"id":"160","span":{"begin":891,"end":894},"obj":"Species"},{"id":"161","span":{"begin":990,"end":994},"obj":"Species"}],"attributes":[{"id":"A141","pred":"tao:has_database_id","subj":"141","obj":"Gene:3700"},{"id":"A142","pred":"tao:has_database_id","subj":"142","obj":"Gene:3700"},{"id":"A143","pred":"tao:has_database_id","subj":"143","obj":"Tax:11676"},{"id":"A144","pred":"tao:has_database_id","subj":"144","obj":"Tax:11676"},{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Tax:10298"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Tax:10310"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"Tax:11216"},{"id":"A148","pred":"tao:has_database_id","subj":"148","obj":"Tax:45659"},{"id":"A149","pred":"tao:has_database_id","subj":"149","obj":"Tax:114727"},{"id":"A150","pred":"tao:has_database_id","subj":"150","obj":"Tax:11320"},{"id":"A151","pred":"tao:has_database_id","subj":"151","obj":"Tax:10245"},{"id":"A152","pred":"tao:has_database_id","subj":"152","obj":"Tax:10244"},{"id":"A153","pred":"tao:has_database_id","subj":"153","obj":"Tax:11631"},{"id":"A154","pred":"tao:has_database_id","subj":"154","obj":"Tax:138950"},{"id":"A155","pred":"tao:has_database_id","subj":"155","obj":"Tax:11149"},{"id":"A156","pred":"tao:has_database_id","subj":"156","obj":"Tax:11149"},{"id":"A157","pred":"tao:has_database_id","subj":"157","obj":"Tax:11149"},{"id":"A158","pred":"tao:has_database_id","subj":"158","obj":"Tax:12814"},{"id":"A159","pred":"tao:has_database_id","subj":"159","obj":"Tax:31604"},{"id":"A160","pred":"tao:has_database_id","subj":"160","obj":"Tax:10244"},{"id":"A161","pred":"tao:has_database_id","subj":"161","obj":"Tax:11631"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T31","span":{"begin":431,"end":445},"obj":"Disease"},{"id":"T32","span":{"begin":436,"end":445},"obj":"Disease"},{"id":"T33","span":{"begin":782,"end":790},"obj":"Disease"},{"id":"T34","span":{"begin":873,"end":883},"obj":"Disease"},{"id":"T35","span":{"begin":1164,"end":1166},"obj":"Disease"}],"attributes":[{"id":"A31","pred":"mondo_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/MONDO_0005460"},{"id":"A32","pred":"mondo_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A33","pred":"mondo_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/MONDO_0002595"},{"id":"A34","pred":"mondo_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/MONDO_0002594"},{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0009973"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T123","span":{"begin":0,"end":5},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T124","span":{"begin":25,"end":31},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T125","span":{"begin":131,"end":133},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T126","span":{"begin":355,"end":357},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T127","span":{"begin":391,"end":396},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T128","span":{"begin":446,"end":447},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T129","span":{"begin":448,"end":453},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T130","span":{"begin":753,"end":758},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T131","span":{"begin":791,"end":796},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T132","span":{"begin":861,"end":866},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T133","span":{"begin":873,"end":879},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9479"},{"id":"T134","span":{"begin":884,"end":889},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T135","span":{"begin":928,"end":933},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T136","span":{"begin":939,"end":943},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T137","span":{"begin":970,"end":972},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T138","span":{"begin":983,"end":988},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T139","span":{"begin":1032,"end":1037},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T140","span":{"begin":1164,"end":1172},"obj":"http://purl.obolibrary.org/obo/CLO_0051806"},{"id":"T141","span":{"begin":1164,"end":1172},"obj":"http://purl.obolibrary.org/obo/CLO_0051808"},{"id":"T142","span":{"begin":1164,"end":1172},"obj":"http://purl.obolibrary.org/obo/CLO_0051894"},{"id":"T143","span":{"begin":1164,"end":1166},"obj":"http://purl.obolibrary.org/obo/CLO_0008770"},{"id":"T144","span":{"begin":1289,"end":1291},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T113","span":{"begin":309,"end":316},"obj":"Chemical"},{"id":"T114","span":{"begin":411,"end":414},"obj":"Chemical"},{"id":"T115","span":{"begin":522,"end":530},"obj":"Chemical"},{"id":"T116","span":{"begin":574,"end":577},"obj":"Chemical"},{"id":"T117","span":{"begin":639,"end":658},"obj":"Chemical"},{"id":"T118","span":{"begin":655,"end":658},"obj":"Chemical"},{"id":"T119","span":{"begin":1164,"end":1166},"obj":"Chemical"},{"id":"T120","span":{"begin":1250,"end":1257},"obj":"Chemical"},{"id":"T121","span":{"begin":1274,"end":1286},"obj":"Chemical"}],"attributes":[{"id":"A113","pred":"chebi_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A114","pred":"chebi_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"},{"id":"A115","pred":"chebi_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"},{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_4705"},{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"},{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_73812"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T29","span":{"begin":531,"end":540},"obj":"http://purl.obolibrary.org/obo/GO_0006810"},{"id":"T30","span":{"begin":839,"end":866},"obj":"http://purl.obolibrary.org/obo/GO_0046718"},{"id":"T31","span":{"begin":845,"end":860},"obj":"http://purl.obolibrary.org/obo/GO_0044409"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T89","span":{"begin":0,"end":71},"obj":"Sentence"},{"id":"T90","span":{"begin":72,"end":134},"obj":"Sentence"},{"id":"T91","span":{"begin":135,"end":196},"obj":"Sentence"},{"id":"T92","span":{"begin":197,"end":322},"obj":"Sentence"},{"id":"T93","span":{"begin":323,"end":430},"obj":"Sentence"},{"id":"T94","span":{"begin":431,"end":592},"obj":"Sentence"},{"id":"T95","span":{"begin":593,"end":700},"obj":"Sentence"},{"id":"T96","span":{"begin":701,"end":781},"obj":"Sentence"},{"id":"T97","span":{"begin":782,"end":872},"obj":"Sentence"},{"id":"T98","span":{"begin":873,"end":973},"obj":"Sentence"},{"id":"T99","span":{"begin":974,"end":1066},"obj":"Sentence"},{"id":"T100","span":{"begin":1067,"end":1178},"obj":"Sentence"},{"id":"T101","span":{"begin":1179,"end":1292},"obj":"Sentence"},{"id":"T102","span":{"begin":1293,"end":1312},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}
2_test
{"project":"2_test","denotations":[{"id":"32667191-23886562-153271","span":{"begin":427,"end":429},"obj":"23886562"},{"id":"32667191-21945220-153272","span":{"begin":589,"end":591},"obj":"21945220"},{"id":"32667191-18505176-153273","span":{"begin":697,"end":699},"obj":"18505176"},{"id":"32667191-24979044-153274","span":{"begin":778,"end":780},"obj":"24979044"},{"id":"32667191-23980510-153275","span":{"begin":869,"end":871},"obj":"23980510"},{"id":"32667191-28040515-153276","span":{"begin":1175,"end":1177},"obj":"28040515"},{"id":"32667191-24524838-153277","span":{"begin":1289,"end":1291},"obj":"24524838"}],"text":"virus shape size (nm) active concentration mechanism of action ref\nHIV-1 spherical 1–10 25 μg/mL interaction with gp120 (11)\nHIV-1 IIIB – 30–50 440 μg/mL interaction with gp120 (19)\nHSV-1, HSV-2, and HPIV-3 – 20–50 not available possible interaction directly with the viral envelope or its protein (20)\nAdenovirus type 3 spherical 5–18 25 μg/mL direct destruction of virus particles and DNA structure (15)\nH1N1 influenza A virus spherical 5–20 12.5 μg/mL inhibition of respiratory enzymes and electron transport components and interference with DNA function (21)\nHBV spherical 10–50 5 μM interaction with double-stranded DNA and/or binding with viral particles (16)\nPPRV spherical 5–30 11.1 μg/mL interaction with virus surface and core (12)\nVaccinia virus spherical 25 not available preventing viral entry into host cells (13)\nMonkey pox virus (MPV) – 10–80 12.5 μg/mL blocking virus-host cell binding and penetration (22)\nTacaribe virus (TCRV) – 5–10 25 μg/mL inactivation of virus particles before entry (23)\nPoliovirus spherical 4–9 3.1 ppm preventing viral particles from binding to the receptors of RD cells (24)\nTGEV spherical \u003c20 12.5 μg/mL direct interaction with TGEV surface protein, such as TGEV S glycoprotein (18)\nlinear 60000–80000\nlinear 20000–30000"}